Shorter Treatment Time For Chagas Could Blunt Kissing Bug Disease
Executive Summary
Chagas is in the spotlight with Novartis, Bayer and DNDi running different trials designed to tackle the neglected tropical parasitic disease.
You may also be interested in...
Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.